BioCentury | Jul 26, 2019
Product Development

Institute for Protein Design's de novo revolution

...exclusive option to acquire PvP upon receipt of Phase I data (see "Gluten-Free Gut" ). Virvio Inc....
BioCentury | Jan 11, 2019
Preclinical News

UW team builds protein that avoids IL-2 toxicities, forms Neoleukin to develop

...company. The University of Washington has previously spun out several companies from Baker’s lab, including Virvio Inc....
BioCentury | Dec 19, 2017
Preclinical News

New stable macrocycles for peptide therapeutics

...spun out several companies that use Baker's platform or mini proteins designed from it, including Virvio Inc....
...another new technique for targeted drug delivery (see BioCentury Extra, Dec. 13) . Mary Romeo University of Washington Virvio Inc....
BioCentury | Dec 13, 2017
Preclinical News

Synthetic virus-like protein complexes could improve drug delivery

...spun out several companies that use Baker's platform or mini proteins designed from it, including Virvio Inc....
BioCentury | Oct 17, 2017
Distillery Therapeutics

Infectious disease

...mini protein before or after viral challenge increased survival compared with vehicle. Next steps by Virvio Inc....
...toxin type B ( C. botulinum toxin B) LICENSING STATUS: Patent applications filed; licensed to Virvio Inc....
...27, 2017 doi:10.1038/nature23912 CONTACT: David Baker, University of Washington, Seattle, Wash. email: dabaker@uw.edu Winnie Pong University of Washington Virvio Inc. Influenza...
BioCentury | Oct 12, 2017
Product R&D

Artificial mini proteins

...from scratch, to bind these targets,” said Baker. “That’s something no one has done before.” Virvio...
...surface antigen -- undergoes a conformational change upon cell entry that is crucial for infectivity. Virvio’s...
...are great targets because you’re putting it right where it needs to be.” Merika Koday, Virvio...
Items per page:
1 - 6 of 6
BioCentury | Jul 26, 2019
Product Development

Institute for Protein Design's de novo revolution

...exclusive option to acquire PvP upon receipt of Phase I data (see "Gluten-Free Gut" ). Virvio Inc....
BioCentury | Jan 11, 2019
Preclinical News

UW team builds protein that avoids IL-2 toxicities, forms Neoleukin to develop

...company. The University of Washington has previously spun out several companies from Baker’s lab, including Virvio Inc....
BioCentury | Dec 19, 2017
Preclinical News

New stable macrocycles for peptide therapeutics

...spun out several companies that use Baker's platform or mini proteins designed from it, including Virvio Inc....
...another new technique for targeted drug delivery (see BioCentury Extra, Dec. 13) . Mary Romeo University of Washington Virvio Inc....
BioCentury | Dec 13, 2017
Preclinical News

Synthetic virus-like protein complexes could improve drug delivery

...spun out several companies that use Baker's platform or mini proteins designed from it, including Virvio Inc....
BioCentury | Oct 17, 2017
Distillery Therapeutics

Infectious disease

...mini protein before or after viral challenge increased survival compared with vehicle. Next steps by Virvio Inc....
...toxin type B ( C. botulinum toxin B) LICENSING STATUS: Patent applications filed; licensed to Virvio Inc....
...27, 2017 doi:10.1038/nature23912 CONTACT: David Baker, University of Washington, Seattle, Wash. email: dabaker@uw.edu Winnie Pong University of Washington Virvio Inc. Influenza...
BioCentury | Oct 12, 2017
Product R&D

Artificial mini proteins

...from scratch, to bind these targets,” said Baker. “That’s something no one has done before.” Virvio...
...surface antigen -- undergoes a conformational change upon cell entry that is crucial for infectivity. Virvio’s...
...are great targets because you’re putting it right where it needs to be.” Merika Koday, Virvio...
Items per page:
1 - 6 of 6